Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in moderately active ulcerative colitis
NCT04607837Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing Etrasimod 2 mg with Placebo (2 arms). Primary endpoint: Percentage of Participants Achieving Clinical Remission at 52 weeks. Started Apr 2021; status: completed.
02
Drugs
etrasimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04607837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607837.